Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

High levels of PTPN11 protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

EMEunice MagalhãesBBBrandon D. Brown

Discussion

Loading...

Member takes

Overview

Observational analysis shows high PTPN11 levels are associated with poor outcomes in acute myelogenous leukemia, indicating targeted therapies may improve survival.

Key Points

  • High PTPN11 protein levels correlate with adverse outcomes in acute myelogenous leukemia, affecting overall survival rates significantly.
  • Patients with high PTPN11 levels experience a 5-year overall survival rate of only 18%, contrasting with better outcomes in low expression cases.
  • Assessment using reverse phase protein arrays reveals that elevated PTPN11 is prognostic, independent of mutation status in acute myelogenous leukemia.
  • These findings highlight the importance of targeting high-risk patients with PTPN11-directed therapies to improve the overall survival outcomes.

Cite This Study

Magalhães et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e3ddhttps://doi.org/10.1182/blood-2025-1700
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Low levels of wilms tumor 1 (WT1) protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia2025
  2. 2TP53 and PPM1D mutations in AML: Distinct frequencies, shared pathway, and adverse prognostic trends2025
  3. 3A blood-based protein signature adds to genomic prognostication of survival in TP53-mutated Acute Myeloid Leukemia2025
  4. 4Low protein expression of Janus kinase 2 (JAK2) is prognostically adverse and independent of mutation status in acute myelogenous leukemia2025
  5. 5Low levels of enhancer of zeste homolog 2 (EZH2) protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia.2025